Yaron Werber expects Forte will report phase 2b celiac and phase 1b alopecia areata data by end of 2026
“we're waiting by the end of this year to get the confirmatory phase two b celiac, study that's randomized and the phase one b data for alopecia areata”
→ Read the source episode
Our resolution criterion
disputableForte publicly reports phase 2b celiac study results and phase 1b alopecia areata data by 2026-12-31
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.